Published in Lab Business Week, April 8th, 2007
PCSC04 is a prospective study of 200 pre-prostate biopsy patients initiated in November 2006 with CMX Research Inc. The study was designed to test whether Miraculins' biomarker diagnostic would be able to reduce the number of unnecessary biopsies when used sequentially with the prostate specific antigen (PSA) test and best clinical care practices.
The Company has completed examination of 130 of the 200...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.